Get key Q3 2025 insights on Vir Biotechnology’s accelerated hepatitis delta trial milestones, strong financials, and upcoming data catalysts.

A research team led by Professor Wang Peng from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences, ...

Shares of Lantheus Holdings declined after the radiopharmaceutical company’s second-quarter earnings results and guidance ...

The immune drugmaker is the second biotech, along with MapLight Therapeutics, to recently use a workaround in U.S. securities ...

Tech trends 2030 are reshaping business. Learn how AI, quantum computing, biotech, and emerging tools will drive the business ...

Unique in the world, Brazil’s Orion Project will integrate a maximum-level biological containment laboratory with the Sirius ...

Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $1.56 per share a year ago. These ...

When Ryan Brazil told her students, “We make space for each other,” she offered a truth that extends well beyond her ...

Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1) Trials of DT-216P2 in Friedreich Ataxia (FA) and DT-168 in Fuchs Endothelial ...

A York biotech company has announced a major move that may see easier and quicker detection of lung cancer in the UK.

X Health (USA) and REVIV Global (UK) today announced a strategic partnership with M42, a global health leader powered by ...

University of Nevada, Reno appoints Anette Saxe as assistant dean of administration to lead finance and operations for CABNR programs statewide.